Xeris Pharmaceuticals Inc. (XERS) Tops Q2 EPS by 2c, provides guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $71.54 million versus the consensus estimate of $63.96 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2025 revenue of $280-290 million, versus the consensus of $269.4 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• KLX Energy narrows Q3 2026 revenue guidance, completes rights offering
• Northrop Grumman wins $143M in new U.S. defense contracts